Peptide
 

Amino acid
sequence

# of
AA

S-S bond

HIV-1IIIB in CEM-SS cells

HSV-2MS in Vero cells

EC50a
(mg/ml)

TC50
(mg/ml)

TI

EC50
(mg/ml)

TC50
(mg/ml)

TI

BMAP-18

GRFKRFRKK
FKKLFKKIS

18

 

0.83

19.8

23.9

27.2

>100

>3.7

SB1 GSKKPVPIIYC
NRRTGKCQRI

21

C11-C18

13.1

>100

>7.6

64.9

>100

>1.5

SB2

GSRRPVPIIYC
NRRTGRCQRI

21

C11-C18

3.33

>100

>30

>100

>100

---

GLK-19

GLKKLLGKLL
KKLGKLLLK

19

 

>47.5

25.1

<0.5

n.e.b

n.e.

 

GLR-19

GLRRLLGRLL
RRLGRLLLR

19

 

4.06

17.8

4.4

2.32

12.4

5.3

GLRC-1

GCRRLLGRLLRRLGRLLCR

19

C2-C18

>100

59.2

<1.0

30

>100

>3.3

GLRC-2

GLRCRLGRLLRRLGRCLLR

19

C4-C16

1.81

17.8

9.83

5.43

31.8

5.9

GLRC-3

GLRRLCGRLGRRLCRLLLR

19

C6-C14

6.37

18.5

2.9

15

62.3

4.2

GLRC-4

GCRRLCGRLGRRLCRLLCR

19

C2-C18
C6-C14

69.3

>100

>1.44

64.7

>100

>1.5

GLRC-5

GLRCRLGRLLRRLGRC

16

C4-C16

>100

59.5

<1.00

n.e.

n.e.

 

GLRC-6

CRLGRLLRRLGRCLLR

16

C1-C13

7.72

41.9

5.43

n.e.

n.e.

 

GLRC-7

CRLGRLLRRLGRC

13

C1-C13

>100

>100

---

n.e.

n.e.

 

GLRC-8

GLRCLRLRGRLRLGRCLLR

19

C4-C16

>100

31

<1.00

n.e.

n.e.

 

Table 1: Antiviral activities of de novo designed peptides. aAlthough not provided in the table, the standard error from multiple antiviral assays is on average less than 10% of the respective mean EC50 or TC50 values. bn.e., not evaluated.
Goto home»